Dawonsys

Dawonsys is a power-electronics company that has operated across nuclear fusion power supplies, plasma power supplies, induction heating equipment, and electric train (rolling stock) manufacturing.

It originally supplied Hyundai Rotem with core components such as propulsion control inverters (CI), but became a full rolling-stock manufacturer after absorbing rail car maker Rowin in 2017.

It then won a series of public-sector orders from Seoul Metro, Korail, and Incheon Transit by underbidding Hyundai Rotem, at one point expanding its domestic electric train market share to roughly 30-40%.

In nuclear fusion power supplies, the company has long supplied high-voltage power equipment to the ITER project, signed an additional contract worth KRW 90bn in 2025, and secured supply deals for Gyrotron-related power systems with Japan's Kyoto Fusioneering and Germany's Max Planck Institute.

Its medical device arm, subsidiary Dawon Medax, has developed Boron Neutron Capture Therapy (BNCT) equipment and is pursuing a KOSDAQ listing targeted for 2026.

However, from 2026 onward, delivery delays and contract cancellations in the rail segment have shaken the entire business structure, with Korail, Seoul Metro, and Incheon Metro Transit notifying cancellation of contracts covering a total of 972 railcars in April of that year.

Because Hyundai Rotem had effectively monopolized the domestic rolling-stock market, Dawonsys's retreat has coincided with a relative strengthening of Hyundai Rotem's position. Roughly 80 small and medium-sized subcontractors are affected, reportedly facing both unpaid production costs and halted deliveries.

Consolidated revenue rose from KRW 209.2bn in 2022 to KRW 357.8bn in 2023, then fell sharply to KRW 301.5bn in 2024 and KRW 112.1bn in 2025. Operating profit swung from a large loss of KRW 159.3bn in 2022 to profits of KRW 19.3bn in 2023 and KRW 7.6bn in 2024, before reverting to a loss of KRW 120.7bn in 2025.

Owner net income also went from a profit of KRW 11.3bn in 2024 to a loss of KRW 197.0bn in 2025, and total equity swung from +KRW 258.9bn at end-2024 to -KRW 515.6bn at end-2025, marking complete capital impairment.

On a quarterly basis, revenue of KRW 28.0bn and an operating loss of KRW 19.3bn in Q3 2025 gave way to a collapse to KRW 4.7bn in revenue in Q4 2025, alongside an operating loss of KRW 63.1bn and an owner net loss of KRW 139.0bn.

This is interpreted as reflecting both a halt in rail production lines and large asset/revenue adjustments booked together.

In Q1 2026, revenue was KRW 21.0bn and the operating loss was KRW 9.5bn, yet owner net income turned positive at +KRW 34.1bn, likely driven by non-operating factors such as gains tied to debt restructuring under the rehabilitation process.

Q2 2026 saw the loss widen again, with an operating loss of KRW 22.9bn and an owner net loss of KRW 25.0bn (revenue for the quarter is not yet finalized in disclosure).

Cumulative owner net loss over the trailing four quarters (Q3 2025-Q2 2026) reached KRW 148.7bn, and operating cash flow remained negative in every period, indicating that the company's earnings and cash-generation base has not yet stabilized.

The domestic urban and regional electric train market has long been an oligopoly effectively dominated by Hyundai Rotem, with Dawonsys entering as a challenger via aggressive low-price bidding after merging with Rowin in 2017.

Public procurement bodies such as Korail, Seoul Metro, and Incheon Transit have long relied on lowest-price-wins bidding under budget constraints, a structure cited as a factor that intensified manufacturers' cost burdens during periods of rising raw material prices.

Within this structure, Dawonsys expanded its market share to roughly 30-40%, but a combination of surging raw material costs and supply-chain disruptions pushed it into a reverse-margin situation where the more it won, the more it lost.

Industry observers warn that if new train deliveries are delayed following the 2026 contract cancellations, actual operational gaps could persist into the early 2030s.

Hyundai Rotem is cited as effectively the only alternative supplier able to fill this gap, and it has recently won a 156-car regional electric train order from Korail, reflecting a relative benefit from Dawonsys's troubles.

The nuclear fusion power supply market, centered on the ITER project, has the character of a long-term, multi-national cooperative undertaking with a different order cycle than the rail business, and contract continuity tends to be relatively high.

The BNCT medical device field remains at an early commercialization stage, with only a small number of companies worldwide reported to hold the relevant technology.

Dawonsys filed for rehabilitation with the Suwon Rehabilitation Court on March 30, 2026, and the court approved the opening of proceedings on April 17, 2026, appointing third-party manager Cho In-cheol and CEO Park Seon-sun as co-managers.

The court-set deadline for submitting a rehabilitation plan was September 1, 2026, which has already passed, so the next steps involve court review of the plan, a creditors' meeting, and a decision on approval.

At the same time, separate from the FY2025 audit opinion disclaimer, the KOSDAQ Market Division of the Korea Exchange designated Dawonsys for a listing eligibility substantive review in June 2026 due to accumulated penalty points from disclosure rule violations, with the Corporate Review Committee to determine delisting or the granting of an improvement period.

The company may submit a management improvement plan ahead of the review, and even if delisting is decided, an appeal process to the KOSDAQ Market Committee remains available.

In the rail segment, the company has stated it is shifting to a more selective order-taking strategy, focused on stable delivery of existing projects and minimizing contingent liabilities.

The nuclear fusion power supply segment continues to serve as a diversification pillar, with ongoing ITER-related contracts, while subsidiary Dawon Medax is reportedly pursuing a KOSDAQ listing targeted for 2026.

A Seoul Central District Prosecutors' Office investigation into alleged fraud related to Korail is also said to be ongoing, and its outcome and any legal liabilities could serve as an additional variable in the company's normalization timeline.